International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratories
S.D. Dertinger1, S. Phonethepswath1, P. Weller1, J. Nicolette2, Jo. Murray2, P. Sonders2, H.W. Vohr3, J. Shi4, L. Krsmanovic4, C. Gleason5, L. Custer5, A. Henwood5, K. Sweder5, L.F. Stankowski6, D.J. Roberts6, A. Giddings7, J. Kenny7, A.M. Lynch7, C. Defrain8, F. Nesslany8, B.J.M. van der Leede9, T. Van Doninck9, A. Schuermans9, K. Tanaka10, Y. Hiwata10, O. Tajima10, E. Wilde11, A. Elhajouji11, W.C. Gunther12, C.J. Thiffeault12, T.J. Shutsky12, R.D. Fiedler12, T. Kimoto13, J.A. Bhalli14, R.H. Heflich14, J.T. MacGregor15
1 Litron Laboratories
2 Abbott Laboratories
3 Bayer Pharma AG
4 BioReliance Corporation
5 Bristol-Myers Squibb
6 Covance Laboratories,
7 GlaxoSmithKline, Ware
8 Institut Pasteur de Lille
9 Janssen Pharmaceutical Companies of Johnson & Johnson
10 Kirin Group Office Co. Ltd.
11 Novartis Institutes for Biomedical Research
12 Pfizer Global R&D
13 Teijin Pharma Ltd.
14 U.S. FDA/NCTR
15 Toxicology Consulting Services
Environmental and Molecular Mutagenesis
Volume 52, Issue 9, December 2011, Pages 690–698